Drugs / Al18F-PSMA-617
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05841992 | Jul 2021 → May 2023 | prostate cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Al18F-PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05841992 ↗ |
| Modality | Diagnostic / imaging agent | “Tracer doses of Al18F-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.” NCT05841992 ↗ |
| Route | Intravenous | “Intravenous injection of one dosage of 0.1mCi/kg Al18F-PSMA-617.” NCT05841992 ↗ |